Molecular Biology Department, Fundacion Instituto de Inmunologia de Colombia, Carrera 50 No. 26-20, Bogota, Colombia.
Vaccine. 2009 Dec 11;28(2):415-21. doi: 10.1016/j.vaccine.2009.10.034. Epub 2009 Oct 17.
This study describes the identification of the Plasmodium vivax rhoptry antigen Pv34 whose sequence was obtained based on homology comparison with the Plasmodium falciparum Pf34. The pv34 gene product was characterized by molecular biology and immunological techniques. Additionally, association of Pv34 to detergent-resistant microdomains (DRMs), expression in late blood-stage parasites and recognition of recombinant Pv34 (rPv34) by sera from P. vivax-infected Aotus monkeys and patients was assessed. Lymphoproliferation and cytokine secretion was also evaluated in individuals living in malaria endemic areas. Altogether, the data support carrying out further studies to assess the immunogenicity and protection-inducing ability of rPv34 as component of a multi-antigenic, multi-stage vaccine against vivax malaria.
本研究描述了对恶性疟原虫裂殖子蛋白 34（Pf34）同源物的鉴定，根据同源性比较，该蛋白被命名为恶性疟原虫裂殖子蛋白 34（Pv34）。采用分子生物学和免疫技术对 pv34 基因产物进行了鉴定。此外，还评估了 Pv34 与去污剂抗性微区（DRMs）的关联、晚期血期寄生虫中的表达以及由感染疟原虫猴和患者的血清识别重组 Pv34（rPv34）的情况。还评估了生活在疟疾流行地区个体的淋巴细胞增殖和细胞因子分泌情况。总之，这些数据支持进一步研究评估 rPv34 的免疫原性和诱导保护能力，作为针对间日疟原虫的多抗原、多阶段疫苗的组成部分。
